A Phase 2a, Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel- Group Study To Evaluate The Safety, Tolerability, And Pharmacodynamics Of Pf-06835919 Administered Once Daily For 6 Weeks In Adults With Nonalcoholic Fatty Liver Disease

Trial Profile

A Phase 2a, Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel- Group Study To Evaluate The Safety, Tolerability, And Pharmacodynamics Of Pf-06835919 Administered Once Daily For 6 Weeks In Adults With Nonalcoholic Fatty Liver Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2018

At a glance

  • Drugs PF 06835919 (Primary)
  • Indications Non-alcoholic fatty liver disease
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 08 Jun 2018 Status changed from recruiting to completed.
    • 27 Mar 2018 Planned End Date changed from 1 Apr 2018 to 30 Apr 2018.
    • 27 Mar 2018 Planned primary completion date changed from 1 Apr 2018 to 30 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top